1047 related articles for article (PubMed ID: 29548607)
1. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
[TBL] [Abstract][Full Text] [Related]
4. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.
Lartey S; Pathirana RD; Zhou F; Jul-Larsen Å; Montomoli E; Wood J; Cox RJ
Hum Vaccin Immunother; 2015; 11(7):1654-62. PubMed ID: 26009966
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
6. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.
Miller MS; Tsibane T; Krammer F; Hai R; Rahmat S; Basler CF; Palese P
J Infect Dis; 2013 Jan; 207(1):98-105. PubMed ID: 23087428
[TBL] [Abstract][Full Text] [Related]
7. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
[TBL] [Abstract][Full Text] [Related]
9. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
10. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
[TBL] [Abstract][Full Text] [Related]
11. Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system.
Friel D; Co M; Ollinger T; Salaun B; Schuind A; Li P; Walravens K; Ennis FA; Vaughn DW
Influenza Other Respir Viruses; 2021 Jan; 15(1):110-120. PubMed ID: 32889792
[TBL] [Abstract][Full Text] [Related]
12. Vaccine-associated enhanced respiratory disease does not interfere with the adaptive immune response following challenge with pandemic A/H1N1 2009.
Gauger PC; Loving CL; Lager KM; Janke BH; Kehrli ME; Roth JA; Vincent AL
Viral Immunol; 2013 Oct; 26(5):314-21. PubMed ID: 24033080
[TBL] [Abstract][Full Text] [Related]
13. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
[TBL] [Abstract][Full Text] [Related]
14. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
15. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.
Islam S; Mohn KG; Krammer F; Sanne M; Bredholt G; Jul-Larsen Å; Tete SM; Zhou F; Brokstad KA; Cox RJ
Vaccine; 2017 Oct; 35(42):5666-5673. PubMed ID: 28899626
[TBL] [Abstract][Full Text] [Related]
16. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
[TBL] [Abstract][Full Text] [Related]
17. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.
Faenzi E; Zedda L; Bardelli M; Spensieri F; Borgogni E; Volpini G; Buricchi F; Pasini FL; Capecchi PL; Montanaro F; Belli R; Lattanzi M; Piccirella S; Montomoli E; Ahmed SS; Rappuoli R; Del Giudice G; Finco O; Castellino F; Galli G
Vaccine; 2012 Jun; 30(27):4086-94. PubMed ID: 22521851
[TBL] [Abstract][Full Text] [Related]
18. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
19. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.
Liu X; Liu Y; Zhang Y; Chen Z; Tang Z; Xu Q; Wang Y; Zhao P; Qi Z
PLoS One; 2013; 8(3):e58810. PubMed ID: 23527030
[TBL] [Abstract][Full Text] [Related]
20. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
